While the identification of actionable biomarkers is fueling huge advancements in precision medicine and targeted therapies for the management of non-small cell lung cancer (NSCLC), access to these tests and associated therapies are not consistent throughout the healthcare system and have the potential to worsen existing health disparities.

Hear from two authors of an ACCC/LUNGevity Foundation study that identified key areas of clinician need related to biomarker testing in NSCLC, including increased guideline familiarity, practical applications of guideline-concordant testing, enhancing patient-clinician discussions and education, and access to appropriate clinical trials.

 

Guests:

Christopher S. Lathan, MD, MS, MPH

Chief Clinical Access and Equity Officer, Dana-Farber Cancer Institute;

Associate Medical Director, Dana-Farber at St. Elizabeth’s Medical Center;

Assistant Professor of Medicine, Harvard Medical School

 

Nikki Martin

Director of Precision Medicine Initiatives

LUNGevity Foundation

 

Related Content:

Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC

[PODCAST] Ep 37: Financial Barriers to Biomarker Testing

[Abstract #123] Identifying barriers to equitable biomarker testing in underserved patients with NSCLC: A mixed-methods study to inform quality improvement opportunities

[Abstract] A United States study focused on patients' understanding of, attitudes towards, and barriers to the use of biomarker testing for NSCLC

Molecular Diagnostics in Non-Small Cell Lung Carcinoma

Advanced NSCLC Biomarker Testing (CME/CMLE on-demand course)

Current and Future Trends in NSCLC Biomarker Testing: The American Experience

Biomarkers for Lung Cancer Screening and Detection

Biomarker Testing for Patients With Advanced NSCLC: Real-World Issues and Tough Choices (ASCO Educational Book)

Biomarkers in Lung Cancer (first page preview only)